MoonLake Immunotherapeutics Cash Flow Conversion Efficiency
MoonLake Immunotherapeutics cash flow conversion efficiency. Based on the latest financial reports, MoonLake Immunotherapeutics (MLTX) has a cash flow conversion efficiency ratio of -0.261x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-66.29 Million) by net assets ($254.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MoonLake Immunotherapeutics (2020–2025)
Cash flow conversion efficiency of MoonLake Immunotherapeutics from 2020 to 2025. This chart illustrates how MoonLake Immunotherapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest MoonLake Immunotherapeutics stock price today for real-time trading data and today's change.
MoonLake Immunotherapeutics Cash Flow Conversion Ratio Explained
MoonLake Immunotherapeutics cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MoonLake Immunotherapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MoonLake Immunotherapeutics ranked by their cash flow conversion efficiency. Also see MoonLake Immunotherapeutics market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vivenio Residencial SOCIMI S.A.
MC:YVIV
|
0.018x |
|
Titagarh Rail Systems Limited
NSE:TITAGARH
|
0.073x |
|
Monex S.A.B. de C.V
MX:MONEXB
|
-1.308x |
|
Danya Cebus
TA:DNYA
|
-0.046x |
|
Chengdu XGimi Technology Co. Ltd. A
SHG:688696
|
-0.021x |
|
Univest Corporation Pennsylvania
NASDAQ:UVSP
|
0.034x |
|
Jaiprakash Power Ventures Limited
NSE:JPPOWER
|
0.082x |
|
Weibo Corp
NASDAQ:WB
|
0.054x |
Annual Cash Flow Conversion Efficiency for MoonLake Immunotherapeutics (2020–2025)
The table below shows the annual cash flow conversion efficiency of MoonLake Immunotherapeutics from 2020 to 2025. Review free cash flow generation of MoonLake Immunotherapeutics to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $304.48 Million | $-196.01 Million | -0.644x | -150.34% |
| 2024-12-31 | $453.39 Million | $-116.59 Million | -0.257x | -208.67% |
| 2023-12-31 | $513.49 Million | $-42.78 Million | -0.083x | +89.75% |
| 2022-12-31 | $68.77 Million | $-55.89 Million | -0.813x | -126.91% |
| 2021-12-31 | $-11.65 Million | $-35.18 Million | 3.021x | +107387.54% |
| 2020-12-31 | $112.48 Million | $-316.69K | -0.003x | -- |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplan… Read more